Quantitative Renal Uptake Using TC99m DMSA in Hypertensive &/or Diabetic Patients.

NCT ID: NCT03123237

Last Updated: 2017-04-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

the investigators explore the possible role of DMSA to detect renal affection in diabetic \&/or hypertensive patients by detecting difference in counts using Tc 99m DMSA in control \& diabetic \&/or hypertensive patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

control will be subjected to:

• Quantitative Tc99m DMSA renal scan using SPECT technique.

Group Type PLACEBO_COMPARATOR

DMSA scan

Intervention Type DIAGNOSTIC_TEST

We explore the possible role of DMSA to detect renal affection in diabetic \&/or hypertensive patients by detecting difference in counts using Tc 99m DMSA in control \& diabetic \&/or hypertensive patients.

Diabetic

diabetic cases will be subjected to:

• Quantitative Tc99m DMSA renal scan using SPECT technique.

Group Type ACTIVE_COMPARATOR

DMSA scan

Intervention Type DIAGNOSTIC_TEST

We explore the possible role of DMSA to detect renal affection in diabetic \&/or hypertensive patients by detecting difference in counts using Tc 99m DMSA in control \& diabetic \&/or hypertensive patients.

Hypertensive

hypertesive cases will be subjected to:

• Quantitative Tc99m DMSA renal scan using SPECT technique.

Group Type ACTIVE_COMPARATOR

DMSA scan

Intervention Type DIAGNOSTIC_TEST

We explore the possible role of DMSA to detect renal affection in diabetic \&/or hypertensive patients by detecting difference in counts using Tc 99m DMSA in control \& diabetic \&/or hypertensive patients.

Diabetic & Hypertensive

Diabetic \& Hypertensive cases will be subjected to:

• Quantitative Tc99m DMSA renal scan using SPECT technique.

Group Type ACTIVE_COMPARATOR

DMSA scan

Intervention Type DIAGNOSTIC_TEST

We explore the possible role of DMSA to detect renal affection in diabetic \&/or hypertensive patients by detecting difference in counts using Tc 99m DMSA in control \& diabetic \&/or hypertensive patients.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DMSA scan

We explore the possible role of DMSA to detect renal affection in diabetic \&/or hypertensive patients by detecting difference in counts using Tc 99m DMSA in control \& diabetic \&/or hypertensive patients.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Patients with diabetes (type2), weather controlled or not.

* Patients with essential hypertension.
* Patients with diabetes \& hypertension.
* Within normal renal function (urea \& creatinine).
* Control cases may be normal individuals (apparently healthy) like donors for renal transplant.

Exclusion Criteria

* • Patients with abnormal renal function.

* Patients with diseases known to affect kidney function rather diabetes \& hypertension e.g. SLE, heart failure or liver cell failure.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hebat Allah Ahmed Askar

Principle investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Assiut university

Asyut, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Heba Askar, MsC

Role: CONTACT

+201003040898

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DMSA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Podocyts Integrity in Glomerular Diseases
NCT05875454 NOT_YET_RECRUITING